Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptinyx Inc.APTX · Entity 120922 | Director | May 26, 2022 | May 31, 2022 |
| Axonics, Inc.AXNX · Entity 86004 | 10% owner | November 02, 2018 | November 02, 2018 |
| BioAge Labs, Inc.BIOA · Entity 5569 | Director | June 10, 2026 | June 12, 2026 |
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director | March 16, 2017 | March 20, 2017 |
| Inozyme Pharma, Inc.INZY · Entity 77717 | 10% owner | April 19, 2022 | April 21, 2022 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | Director | August 31, 2026 | September 02, 2026 |
| Lexeo Therapeutics, Inc.LXEO · Entity 5687 | 10% owner | November 07, 2023 | November 10, 2023 |
| Molecular Templates, Inc.MTEM · Entity 85987 | 10% owner | August 28, 2020 | September 01, 2020 |
| Tourmaline Bio, Inc.TALS · Entity 15643 | 10% owner | May 11, 2021 | May 11, 2021 |
| Vaxcyte, Inc.PCVX · Entity 1164 | 10% owner | June 11, 2020 | June 11, 2020 |
| Venus Concept Inc.VERO · Entity 55304 | 10% owner | November 07, 2019 | November 08, 2019 |
| Vera Therapeutics, Inc.VERA · Entity 4358 | Director | May 21, 2026 | May 26, 2026 |
| Veradermics, IncMANE · Entity 1907 | Director · 10% owner | February 03, 2026 | February 06, 2026 |
| Zenas BioPharma, Inc.ZBIO · Entity 275 | Director | June 15, 2026 | June 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptinyx Inc.
Report date May 26, 2022 · Filed May 31, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2032-05-25 | Direct | 40,000 |
Reported balance
After 2022-05-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-26 · Grant · Acquired 40,000 · Balance 40,000 F1: This option vests in ratable monthly installments over one year from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in ratable monthly installments over one year from the date of grant.
Axonics, Inc.
Report date November 02, 2018 · Filed November 02, 2018
Jointly reported with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Longitude Venture Partners III, L.P. | 2,933,333 |
Last balance in matching sequence
After 2018-11-02 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-11-02 · Conversion · Acquired 2,400,000 · Balance 2,400,000 F1: Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018. F2: Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The Series C preferred stock had no expiration date. F3: These shares are held directly by Longitude Venture Partners III, L.P. ("Longitude Venture III"). Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker, a member of the Issuer's board of directors, are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Row 2 · 2018-11-02 · Purchase · Acquired 533,333 · Balance 2,933,333 F1: Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018. F3: These shares are held directly by Longitude Venture Partners III, L.P. ("Longitude Venture III"). Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker, a member of the Issuer's board of directors, are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Longitude Venture Partners III, L.P. | 0 |
Reported balance
After 2018-11-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-11-02 · Conversion · Disposed 2,000,000 · Balance 0 F2: Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The Series C preferred stock had no expiration date. F1: Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018. F3: These shares are held directly by Longitude Venture Partners III, L.P. ("Longitude Venture III"). Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker, a member of the Issuer's board of directors, are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a 1.2-for-1 forward stock split of the Issuer's common stock effected on October 18, 2018.
F2: Effective upon the closing of the Issuer's initial public offering of its common stock under the Securities Act of 1933, as amended, each share of Series C preferred stock automatically converted into 1.2 shares of the Issuer's common stock. The Series C preferred stock had no expiration date.
F3: These shares are held directly by Longitude Venture Partners III, L.P. ("Longitude Venture III"). Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker, a member of the Issuer's board of directors, are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
BioAge Labs, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.48 · Expires 2036-06-09 | Direct | 22,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 22,000 · Balance 22,000 F1: The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.
CORCEPT THERAPEUTICS INC
Report date March 16, 2017 · Filed March 20, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LVP | 5,721,372 |
Reported balance
After 2017-03-16 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2017-03-16 · Sale · Disposed 264,650 · Balance 5,721,372 F1: Reflects sales of common stock of the Issuer executed in multiple transactions at prices ranging from $9.855 to $10.255 per share. The price reported reflects the weighted-average price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F2: Reflects the pro rata distribution by Longitude Venture Partners, L.P. ("LVP") and Longitude Capital Partners, L.P. ("LCA") on March 16, 2017 of shares of common stock of the Issuer to their respective partners for no consideration, and the subsequent pro rata distribution by Longitude Capital Partners, LLC ("LCP"), the sole general partner of LVP and LCA, on March 16, 2017 of shares of common stock of the Issuer to its members for no consideration. As a result of these distributions, the Reporting Person received and became the direct holder of 68,071 shares of common stock of the Issuer. F3: Reflects shares of common stock of the Issuer held of record by LVP and LCA. Mr. Enright is a managing member of LCP, the sole general partner of LVP and LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP and LCA, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy LCA | 114,675 |
Reported balance
After 2017-03-16 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2017-03-16 · Sale · Disposed 5,305 · Balance 114,675 F1: Reflects sales of common stock of the Issuer executed in multiple transactions at prices ranging from $9.855 to $10.255 per share. The price reported reflects the weighted-average price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F2: Reflects the pro rata distribution by Longitude Venture Partners, L.P. ("LVP") and Longitude Capital Partners, L.P. ("LCA") on March 16, 2017 of shares of common stock of the Issuer to their respective partners for no consideration, and the subsequent pro rata distribution by Longitude Capital Partners, LLC ("LCP"), the sole general partner of LVP and LCA, on March 16, 2017 of shares of common stock of the Issuer to its members for no consideration. As a result of these distributions, the Reporting Person received and became the direct holder of 68,071 shares of common stock of the Issuer. F3: Reflects shares of common stock of the Issuer held of record by LVP and LCA. Mr. Enright is a managing member of LCP, the sole general partner of LVP and LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP and LCA, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 272,281 |
Reported balance
Holding disclosure · report date 2017-03-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 272,281 F2: Reflects the pro rata distribution by Longitude Venture Partners, L.P. ("LVP") and Longitude Capital Partners, L.P. ("LCA") on March 16, 2017 of shares of common stock of the Issuer to their respective partners for no consideration, and the subsequent pro rata distribution by Longitude Capital Partners, LLC ("LCP"), the sole general partner of LVP and LCA, on March 16, 2017 of shares of common stock of the Issuer to its members for no consideration. As a result of these distributions, the Reporting Person received and became the direct holder of 68,071 shares of common stock of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects sales of common stock of the Issuer executed in multiple transactions at prices ranging from $9.855 to $10.255 per share. The price reported reflects the weighted-average price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F2: Reflects the pro rata distribution by Longitude Venture Partners, L.P. ("LVP") and Longitude Capital Partners, L.P. ("LCA") on March 16, 2017 of shares of common stock of the Issuer to their respective partners for no consideration, and the subsequent pro rata distribution by Longitude Capital Partners, LLC ("LCP"), the sole general partner of LVP and LCA, on March 16, 2017 of shares of common stock of the Issuer to its members for no consideration. As a result of these distributions, the Reporting Person received and became the direct holder of 68,071 shares of common stock of the Issuer.
F3: Reflects shares of common stock of the Issuer held of record by LVP and LCA. Mr. Enright is a managing member of LCP, the sole general partner of LVP and LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP and LCA, except to the extent of his pecuniary interest therein.
Inozyme Pharma, Inc.
Report date April 19, 2022 · Filed April 21, 2022
Jointly reported with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., Tammenoms Bakker Juliet
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Longitude Venture Partners III, L.P. | 4,174,379 |
Reported balance
After 2022-04-19 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-04-19 · Purchase · Acquired 1,355,000 · Balance 4,174,379 F1: These shares are held by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and dispositive power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and dispositive power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Jazz Pharmaceuticals plc
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 21,278 |
Ending reported balance
After 2026-08-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-31 · Tax withholding · Disposed 14 · Balance 22,970 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Row 2 · 2026-08-31 · Tax withholding · Disposed 1,692 · Balance 21,278 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
Lexeo Therapeutics, Inc.
Report date November 07, 2023 · Filed November 10, 2023
Jointly reported with Longitude Capital Partners IV, LLC, Longitude Venture Partners IV, L.P., Tammenoms Bakker Juliet
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Longitude Venture Partners IV, L.P. | 2,567,100 |
Last balance in matching sequence
After 2023-11-07 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2023-11-07 · Conversion · Acquired 1,793,429 · Balance 1,793,429 F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date. F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Row 2 · 2023-11-07 · Conversion · Acquired 319,126 · Balance 2,112,555 F3: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Row 3 · 2023-11-07 · Purchase · Acquired 454,545 · Balance 2,567,100 F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series A convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Longitude Venture Partners IV, L.P. | 0 |
Reported balance
After 2023-11-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-11-07 · Conversion · Disposed 18,999,999 · Balance 0 F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date. F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security | IndirectBy Longitude Venture Partners IV, L.P. | 0 |
Reported balance
After 2023-11-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-11-07 · Conversion · Disposed 2,906,148 · Balance 0 F3: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.
F2: These shares are held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to have voting and dispositive power over the shares held by LVP IV. Mr. Enright and Ms. Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and dispositive power with respect to the shares held by LVP IV. Each of LCP IV, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F3: Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.
Molecular Templates, Inc.
Report date August 28, 2020 · Filed September 01, 2020
Jointly reported with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., Tammenoms Bakker Juliet
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2020-08-28 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2020-08-28 · Sale · Disposed 2,447 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.63 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2: These shares were held directly by Juliet Tammenoms Bakker ("Ms. Bakker"). |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2020-08-28 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2020-08-28 · Sale · Disposed 1,049 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.63 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3: These shares were held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,495 |
Reported balance
Holding disclosure · report date 2020-08-28 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 3,495 F5: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Longitude Venture Partners III, L.P. | 3,199,035 |
Reported balance
Holding disclosure · report date 2020-08-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,199,035 F4: These shares are held by Longitude Venture Partners III, L.P. ("Longitude Venture III"). This report is filed jointly by Longitude Capital Partners III, LLC ("Longitude Capital III"), Longitude Venture III, Patrick G. Enright ("Mr. Enright"), and Ms. Bakker. Longitude Capital III is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power over the shares held by Longitude Venture III. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital III and may be deemed to share voting, investment and dispositive power over the shares held by Longitude Venture III. Each of Longitude Capital III, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.63 to $10.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2: These shares were held directly by Juliet Tammenoms Bakker ("Ms. Bakker").
F3: These shares were held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F4: These shares are held by Longitude Venture Partners III, L.P. ("Longitude Venture III"). This report is filed jointly by Longitude Capital Partners III, LLC ("Longitude Capital III"), Longitude Venture III, Patrick G. Enright ("Mr. Enright"), and Ms. Bakker. Longitude Capital III is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power over the shares held by Longitude Venture III. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital III and may be deemed to share voting, investment and dispositive power over the shares held by Longitude Venture III. Each of Longitude Capital III, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.
F5: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
Tourmaline Bio, Inc.
Report date May 11, 2021 · Filed May 11, 2021
Jointly reported with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., Tammenoms Bakker Juliet
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Longitude Venture Partners III, L.P. | 3,220,775 |
Last balance in matching sequence
After 2021-05-11 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-05-11 · Conversion · Acquired 2,985,775 · Balance 2,985,775 F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Row 2 · 2021-05-11 · Purchase · Acquired 235,000 · Balance 3,220,775 F3: On May 11, 2021, LVP III purchased 235,000 shares of Common Stock of the Issuer at a price of $17.00 per share pursuant to an underwritten public offering. F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Longitude Venture Partners III, L.P. | 0 |
Reported balance
After 2021-05-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-05-11 · Conversion · Disposed 1,308,410 · Balance 0 F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectBy Longitude Venture Partners III, L.P. | 0 |
Reported balance
After 2021-05-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-05-11 · Conversion · Disposed 1,271,027 · Balance 0 F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Longitude Venture Partners III, L.P. | 0 |
Reported balance
After 2021-05-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-05-11 · Conversion · Disposed 406,338 · Balance 0 F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date. F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series A-1 Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. Each share of Series B Preferred Stock converted into common stock on a 1-for-5.35 basis automatically upon the closing of the Issuer's initial public offering. The Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock had no expiration date.
F2: These shares are held by Longitude Venture Partners III, L.P ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting and investment power over the shares held by LVP III. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of LCP III and may be deemed to share voting and investment power with respect to the shares held by LVP III. Each of LCP III, Mr. Enright and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F3: On May 11, 2021, LVP III purchased 235,000 shares of Common Stock of the Issuer at a price of $17.00 per share pursuant to an underwritten public offering.
Vaxcyte, Inc.
Report date June 11, 2020 · Filed June 11, 2020
Jointly reported with Longitude Capital Partners II, LLC, Longitude Venture Partners II, L.P., Tammenoms Bakker Juliet
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Longitude Venture Partners II, L.P. | Not disclosed |
Reported balance
Holding disclosure · report date 2020-06-11 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Series A Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series A Preferred Stock will be converted into shares of Common Stock for no consideration. F2: The securities are held of record by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC, ("LCP2"), the general partner of Longitude II, may be deemed to have voting, investment and dispositive power with respect to the shares held by Longitude II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP2 and may be deemed to have voting, investment and dispositive power over the shares held by Longitude II. Each of LCP2, Mr. Enright and Ms. Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Longitude Venture Partners II, L.P. | Not disclosed |
Reported balance
Holding disclosure · report date 2020-06-11 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F3: The Series B Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series B Preferred Stock will be converted into shares of Common Stock for no consideration. F2: The securities are held of record by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC, ("LCP2"), the general partner of Longitude II, may be deemed to have voting, investment and dispositive power with respect to the shares held by Longitude II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP2 and may be deemed to have voting, investment and dispositive power over the shares held by Longitude II. Each of LCP2, Mr. Enright and Ms. Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Longitude Venture Partners II, L.P. | Not disclosed |
Reported balance
Holding disclosure · report date 2020-06-11 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F4: The Series C Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series C Preferred Stock will be converted into shares of Common Stock for no consideration. F2: The securities are held of record by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC, ("LCP2"), the general partner of Longitude II, may be deemed to have voting, investment and dispositive power with respect to the shares held by Longitude II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP2 and may be deemed to have voting, investment and dispositive power over the shares held by Longitude II. Each of LCP2, Mr. Enright and Ms. Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectBy Longitude Venture Partners II, L.P. | Not disclosed |
Reported balance
Holding disclosure · report date 2020-06-11 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F5: The Series D Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series D Preferred Stock will be converted into shares of Common Stock for no consideration. F2: The securities are held of record by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC, ("LCP2"), the general partner of Longitude II, may be deemed to have voting, investment and dispositive power with respect to the shares held by Longitude II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP2 and may be deemed to have voting, investment and dispositive power over the shares held by Longitude II. Each of LCP2, Mr. Enright and Ms. Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series A Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series A Preferred Stock will be converted into shares of Common Stock for no consideration.
F2: The securities are held of record by Longitude Venture Partners II, L.P. ("Longitude II"). Longitude Capital Partners II, LLC, ("LCP2"), the general partner of Longitude II, may be deemed to have voting, investment and dispositive power with respect to the shares held by Longitude II. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP2 and may be deemed to have voting, investment and dispositive power over the shares held by Longitude II. Each of LCP2, Mr. Enright and Ms. Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.
F3: The Series B Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series B Preferred Stock will be converted into shares of Common Stock for no consideration.
F4: The Series C Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series C Preferred Stock will be converted into shares of Common Stock for no consideration.
F5: The Series D Preferred Stock is convertible into Common Stock on a 1:1 basis and has no expiration date. Immediately prior to the consummation of the Issuer's initial public offering, all shares of Series D Preferred Stock will be converted into shares of Common Stock for no consideration.
Venus Concept Inc.
Report date November 07, 2019 · Filed November 08, 2019
Jointly reported with Longitude Capital Partners II, LLC, Longitude Venture Partners II, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Longitude Venture Partners II, L.P | 3,666,119 |
Reported balance
Holding disclosure · report date 2019-11-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,666,119 F1: These shares were received in connection with the merger of a wholly-owned subsidiary of Restoration Robotics, Inc. with and into Venus Concept Ltd. (the "Merger") (i) 3,476,583 were received, in exchange for 2,192,736 shares, 3,287,420 shares and 548,185 shares of Series A Preferred Stock, Series B Preferred Stock and ordinary shares of Venus Concept Ltd., respectively and (ii) 189,535 were received, upon the conversion of the outstanding principal and any accrued and unpaid interest of three 8% Convertible Promissory Notes issued by Venus Concept Ltd., dated as of June 25, 2019, August 14, 2019 and August 21, 2019, in the original principal amounts of $300,000, $197,142.85 and $802,857.15, respectively. F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude Venture II"). Longitude Capital Partners II, LLC ("Longitude Capital II") is the general partner of Longitude Venture II and may be deemed to have shared voting, investment and dispositive power with respect to these securities. Ms. Tammenoms Bakker, who is a member of the Issuer's board of directors, and Patrick G. Enright, are the managing members of Longitude Capital II (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital II and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were received in connection with the merger of a wholly-owned subsidiary of Restoration Robotics, Inc. with and into Venus Concept Ltd. (the "Merger") (i) 3,476,583 were received, in exchange for 2,192,736 shares, 3,287,420 shares and 548,185 shares of Series A Preferred Stock, Series B Preferred Stock and ordinary shares of Venus Concept Ltd., respectively and (ii) 189,535 were received, upon the conversion of the outstanding principal and any accrued and unpaid interest of three 8% Convertible Promissory Notes issued by Venus Concept Ltd., dated as of June 25, 2019, August 14, 2019 and August 21, 2019, in the original principal amounts of $300,000, $197,142.85 and $802,857.15, respectively.
F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude Venture II"). Longitude Capital Partners II, LLC ("Longitude Capital II") is the general partner of Longitude Venture II and may be deemed to have shared voting, investment and dispositive power with respect to these securities. Ms. Tammenoms Bakker, who is a member of the Issuer's board of directors, and Patrick G. Enright, are the managing members of Longitude Capital II (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital II and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Vera Therapeutics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.35 · Expires 2036-05-20 | Direct | 17,084 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 17,084 · Balance 17,084 F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.
Veradermics, Inc
Report date February 03, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,236,631 |
Reported balance
After 2026-02-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-02-05 · Conversion · Acquired 1,236,631 · Balance 1,236,631 F1: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2: These shares are held by Longitude Venture Partners V, L.P. ("LVPV"). Longitude Capital Partners V, LLC ("LCPV"), is the general partner of LVPV and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of LCPV, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of LCPV, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,407,752 |
Reported balance
After 2026-02-05 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-02-05 · Conversion · Acquired 1,171,121 · Balance 2,407,752 F3: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2: These shares are held by Longitude Venture Partners V, L.P. ("LVPV"). Longitude Capital Partners V, LLC ("LCPV"), is the general partner of LVPV and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of LCPV, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of LCPV, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,171,121 |
Reported balance
After 2026-02-05 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-02-05 · Conversion · Acquired 1,171,121 · Balance 1,171,121 F3: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F4: These shares are held by Longitude 103.8 East, L.P. ("L103"). Longitude 103.8 East Partners, LLC ("L103P") is the general partner of L103 and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of L103P, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of L103P, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,600,399 |
Reported balance
After 2026-02-05 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-02-05 · Purchase · Acquired 192,647 · Balance 2,600,399 F2: These shares are held by Longitude Venture Partners V, L.P. ("LVPV"). Longitude Capital Partners V, LLC ("LCPV"), is the general partner of LVPV and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of LCPV, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of LCPV, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,053,474 |
Reported balance
After 2026-02-05 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-02-05 · Purchase · Acquired 882,353 · Balance 2,053,474 F4: These shares are held by Longitude 103.8 East, L.P. ("L103"). Longitude 103.8 East Partners, LLC ("L103P") is the general partner of L103 and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of L103P, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of L103P, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-05 · Conversion · Disposed 1,236,631 · Balance 0 F1: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-05 · Conversion · Disposed 1,171,121 · Balance 0 F3: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-05 · Conversion · Disposed 1,171,121 · Balance 0 F3: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-02-03 | Direct | 45,131 |
Reported balance
After 2026-02-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-03 · Grant · Acquired 45,131 · Balance 45,131 F5: This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
F2: These shares are held by Longitude Venture Partners V, L.P. ("LVPV"). Longitude Capital Partners V, LLC ("LCPV"), is the general partner of LVPV and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of LCPV, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of LCPV, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.
F3: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
F4: These shares are held by Longitude 103.8 East, L.P. ("L103"). Longitude 103.8 East Partners, LLC ("L103P") is the general partner of L103 and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of L103P, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of L103P, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.
F5: This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date.
Zenas BioPharma, Inc.
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.71 · Expires 2036-06-15 | Direct | 18,500 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 18,500 · Balance 18,500 F1: The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service.
Past disclosures · reporting ended (8)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
89bio, Inc.
Report date November 16, 2020 · Filed November 18, 2020
Jointly reported with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., Tammenoms Bakker Juliet
Section 16 reporting ended · disclosed 2020-11-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,750,877 |
Reported balance
After 2020-11-16 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-11-16 · Other · Disposed 850,000 · Balance 1,750,877 F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("Longitude Venture III") to its general and limited partners. F2: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,973 |
Reported balance
After 2020-11-16 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-11-16 · Other · Acquired 2,973 · Balance 2,973 F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members. F4: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,080 |
Reported balance
After 2020-11-16 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2020-11-16 · Other · Acquired 2,080 · Balance 2,080 F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members. F5: These shares are held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 891 |
Reported balance
After 2020-11-16 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2020-11-16 · Other · Acquired 891 · Balance 891 F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members. F6: These shares are held directly by Ms. Bakker. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("Longitude Venture III") to its general and limited partners.
F2: These shares are held directly by Longitude Venture III. Longitude Capital Partners III, LLC ("Longitude Capital III") is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of Longitude Capital III and the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Capital III to its members.
F4: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F5: These shares are held by a trust. Ms. Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Ms. Bakker, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F6: These shares are held directly by Ms. Bakker.
Aimmune Therapeutics, Inc.
Report date October 10, 2020 · Filed October 14, 2020
Section 16 reporting ended · disclosed 2020-10-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-10 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2020-10-10 · Other · Disposed 70,561 · Balance 0 |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2020-10-13 · Disposition to issuer · Disposed 7,840 · Balance 0 F2: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price"). F3: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | IndirectBy: LCP2 | 0 |
Reported balance
After 2020-10-10 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-10-10 · Other · Disposed 91,697 · Balance 0 F1: Reflects shares held by Longitude Capital Partners II, LLC ("LCP2"). The Reporting Person is a managing member of LCP2 and in his capacity as such may be deemed to share voting and investment power over the shares held by LCP2. The Reporting Person disclaims beneficial ownership over these securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.14 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-13 · Disposition to issuer · Disposed 65,849 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.29 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-13 · Disposition to issuer · Disposed 52,421 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.40 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-13 · Disposition to issuer · Disposed 19,755 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.26 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-10-13 · Disposition to issuer · Disposed 17,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.79 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-10-13 · Disposition to issuer · Disposed 7,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.90 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-10-13 · Disposition to issuer · Disposed 11,432 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.11 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-10-13 · Disposition to issuer · Disposed 15,398 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares held by Longitude Capital Partners II, LLC ("LCP2"). The Reporting Person is a managing member of LCP2 and in his capacity as such may be deemed to share voting and investment power over the shares held by LCP2. The Reporting Person disclaims beneficial ownership over these securities and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
F2: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price").
F3: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
COLLEGIUM PHARMACEUTICAL, INC
Report date December 08, 2017 · Filed December 12, 2017
Jointly reported with Longitude Capital Partners, LLC, Tammenoms Bakker Juliet, Longitude Capital Associates, L.P., Longitude Venture Partners L.P.
Section 16 reporting ended · disclosed 2017-12-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LVP | 2,276,222 |
Reported balance
After 2017-12-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-12-08 · Sale · Disposed 980,350 · Balance 2,276,222 F1: This report is filed jointly by Longitude Capital Partners, LLC ("LCP"), Longitude Venture Partners, L.P. ("LVP"), Longitude Capital Associates, L.P. ("LCA"), Patrick G. Enright ("Enright") and Juliet Tammenoms Bakker ("Bakker"). LCP is the general partner of LVP and LCA, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of Enright and Bakker is a managing member of LCP, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of LCP, Enright and Bakker disclaims beneficial ownership of the securities of the Issuer held by LVP and LCA except to the extent of their respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy LCA | 45,620 |
Reported balance
After 2017-12-08 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2017-12-08 · Sale · Disposed 19,650 · Balance 45,620 F1: This report is filed jointly by Longitude Capital Partners, LLC ("LCP"), Longitude Venture Partners, L.P. ("LVP"), Longitude Capital Associates, L.P. ("LCA"), Patrick G. Enright ("Enright") and Juliet Tammenoms Bakker ("Bakker"). LCP is the general partner of LVP and LCA, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of Enright and Bakker is a managing member of LCP, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of LCP, Enright and Bakker disclaims beneficial ownership of the securities of the Issuer held by LVP and LCA except to the extent of their respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: This report is filed jointly by Longitude Capital Partners, LLC ("LCP"), Longitude Venture Partners, L.P. ("LVP"), Longitude Capital Associates, L.P. ("LCA"), Patrick G. Enright ("Enright") and Juliet Tammenoms Bakker ("Bakker"). LCP is the general partner of LVP and LCA, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of Enright and Bakker is a managing member of LCP, has the power to vote and dispose of the securities of the Issuer held by each of LVP and LCA, and may be deemed to have beneficial ownership of such securities. Each of LCP, Enright and Bakker disclaims beneficial ownership of the securities of the Issuer held by LVP and LCA except to the extent of their respective pecuniary interest therein.
Eargo, Inc.
Report date April 14, 2021 · Filed April 16, 2021
Jointly reported with Longitude Venture Partners IV, L.P., Longitude Capital Partners IV, LLC
Section 16 reporting ended · disclosed 2021-04-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,918,691 |
Reported balance
After 2021-04-14 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-04-14 · Other · Disposed 1,000,000 · Balance 2,918,691 F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners IV, L.P. ("LVP4") to its general and limited partners, pursuant to a Rule 10b5-1 trading plan. F2: These shares are held directly by LVP4. Longitude Capital Partners IV, LLC ("LCP4") is the general partner of LVP4 and may be deemed to have voting, investment and dispositive power over the shares held by LVP4. Juliet Tammenoms Bakker, a member of the Issuer's board of directors, and Patrick G. Enright are managing members of LCP4 (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to the shares held by LVP4. Each of LCP4 and the Managers disclaims beneficial ownership of the shares held by LVP4 and this report shall not be deemed an admission that any of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. F3: (Continued from footnote 2) Juliet Tammenoms Bakker, a managing member of LCP4, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 5,012 |
Reported balance
After 2021-04-14 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-04-14 · Other · Acquired 5,012 · Balance 5,012 F4: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP4 to its members. F5: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners IV, L.P. ("LVP4") to its general and limited partners, pursuant to a Rule 10b5-1 trading plan.
F2: These shares are held directly by LVP4. Longitude Capital Partners IV, LLC ("LCP4") is the general partner of LVP4 and may be deemed to have voting, investment and dispositive power over the shares held by LVP4. Juliet Tammenoms Bakker, a member of the Issuer's board of directors, and Patrick G. Enright are managing members of LCP4 (each a "Manager" and collectively, the "Managers") and may each be deemed to share voting, investment and dispositive power with respect to the shares held by LVP4. Each of LCP4 and the Managers disclaims beneficial ownership of the shares held by LVP4 and this report shall not be deemed an admission that any of them is the beneficial owner of such shares for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F3: (Continued from footnote 2) Juliet Tammenoms Bakker, a managing member of LCP4, currently serves on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer.
F4: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP4 to its members.
F5: These shares are held by a limited partnership (the "Partnership") of which the general partner is a trust (the "Trust"). Mr. Enright is the Trustee of the Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership. Each of the Trust and Mr. Enright disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Enright, disclaims beneficial ownership of these securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
KALA BIO, Inc.
Report date July 25, 2017 · Filed July 27, 2017
Jointly reported with Longitude Capital Partners II, LLC, Tammenoms Bakker Juliet, Longitude Venture Partners II, L.P.
Section 16 reporting ended · disclosed 2017-07-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Longitude Venture Partners II, L.P. | 2,270,946 |
Last balance in matching sequence
After 2017-07-25 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-07-25 · Conversion · Acquired 2,055,946 · Balance 2,055,946 F1: The Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: This Form 4 is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this Form 4. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein. F3: Longitude Venture II acquired 215,000 shares of Common Stock in the Issuer's initial public offering. Row 2 · 2017-07-25 · Purchase · Acquired 215,000 · Balance 2,270,946 F2: This Form 4 is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this Form 4. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein. F3: Longitude Venture II acquired 215,000 shares of Common Stock in the Issuer's initial public offering. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Longitude Venture Partners II, L.P. | 0 |
Reported balance
After 2017-07-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-07-25 · Conversion · Disposed 10,707,985 · Balance 0 F1: The Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: This Form 4 is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this Form 4. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein. F3: Longitude Venture II acquired 215,000 shares of Common Stock in the Issuer's initial public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2: This Form 4 is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom shared beneficial ownership of more than 10% of the capital stock of the Issuer as of the date of the transactions reported in this Form 4. Longitude Capital II is the general partner of Longitude Venture II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are the managing members of Longitude Capital II and may be deemed to share voting and investment power over the shares held by Longitude Venture II. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.
F3: Longitude Venture II acquired 215,000 shares of Common Stock in the Issuer's initial public offering.
RAPID MICRO BIOSYSTEMS, INC.
Report date February 04, 2026 · Filed February 06, 2026
Jointly reported with Longitude Capital Partners II, LLC, Longitude Venture Partners II, L.P., Longitude Prime Partners, LLC, Longitude Prime Fund, L.P., Tammenoms Bakker Juliet
Section 16 reporting ended · disclosed 2026-02-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectHeld by Longitude Prime Fund, L.P. | 0 |
Reported balance
After 2026-02-04 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-02-04 · Sale · Disposed 49,000 · Balance 0 F1: The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and dispositive power with respect to the shares held by LPF. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP and may be deemed to have voting and dispositive power over the shares held by LPF. LPP and each of Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. |
| Class A Common StockSEC Table I · non-derivative | IndirectHeld by Longitude Venture Partners II, L.P. | 4,029,245 |
Reported balance
Holding disclosure · report date 2026-02-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,029,245 F2: The securities are held directly by LVPII. Longitude Capital Partners II, LLC, ("LCPII"), the general partner of LVPII, may be deemed to have voting and dispositive power with respect to the shares held by LVPII. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPII and may be deemed to share voting and dispositive power over the shares held by LVPII. Each of LCPII, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and dispositive power with respect to the shares held by LPF. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP and may be deemed to have voting and dispositive power over the shares held by LPF. LPP and each of Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.
F2: The securities are held directly by LVPII. Longitude Capital Partners II, LLC, ("LCPII"), the general partner of LVPII, may be deemed to have voting and dispositive power with respect to the shares held by LVPII. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPII and may be deemed to share voting and dispositive power over the shares held by LVPII. Each of LCPII, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.
Sierra Oncology, Inc.
Report date April 27, 2022 · Filed April 29, 2022
Jointly reported with Longitude Capital Partners III, LLC, Longitude Venture Partners III, L.P., Tammenoms Bakker Juliet, Longitude Prime Partners, LLC, Longitude Prime Fund, L.P.
Section 16 reporting ended · disclosed 2022-04-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2022-04-27 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-04-27 · Other · Disposed 175,000 · Balance 0 F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Prime Fund, L.P. ("LPF") to its general and limited partners. F2: The securities are held directly by LPF. Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting, investment and dispositive power over such securities. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2022-04-27 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2022-04-27 · Other · Disposed 1,964,771 · Balance 0 F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("LVP III") to its general and limited partners. F4: These securities are held directly by LVP III. Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Each of LCP III, Mr. Enright, and Ms. Tammenoms Bakker disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 5,023 |
Reported balance
After 2022-04-27 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2022-04-27 · Other · Acquired 5,023 · Balance 5,023 F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F6: These shares are held directly by Juliet Tammenoms Bakker. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,152 |
Reported balance
After 2022-04-27 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2022-04-27 · Other · Acquired 2,152 · Balance 2,152 F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F7: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 7,175 |
Reported balance
After 2022-04-27 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2022-04-27 · Other · Acquired 7,175 · Balance 7,175 F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members. F8: These shares are held directly by Patrick G. Enright. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 5,611 |
Reported balance
After 2022-04-27 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2022-04-27 · Other · Acquired 588 · Balance 5,611 F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F6: These shares are held directly by Juliet Tammenoms Bakker. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,404 |
Reported balance
After 2022-04-27 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2022-04-27 · Other · Acquired 252 · Balance 2,404 F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F7: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 8,015 |
Reported balance
After 2022-04-27 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2022-04-27 · Other · Acquired 840 · Balance 8,015 F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members F8: These shares are held directly by Patrick G. Enright. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Prime Fund, L.P. ("LPF") to its general and limited partners.
F2: The securities are held directly by LPF. Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and investment power with respect to the shares held by LPF. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting, investment and dispositive power over such securities. Each of LPP, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F3: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Longitude Venture Partners III, L.P. ("LVP III") to its general and limited partners.
F4: These securities are held directly by LVP III. Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Each of LCP III, Mr. Enright, and Ms. Tammenoms Bakker disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F5: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LCP III to its members.
F6: These shares are held directly by Juliet Tammenoms Bakker.
F7: These shares are held by a trust. Juliet Tammenoms Bakker is the Investment Trustee of such trust and may be deemed to share voting and dispositive power with regard to the reported shares. Ms. Tammenoms Bakker disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
F8: These shares are held directly by Patrick G. Enright.
F9: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by LPP to its members
Tricida, Inc.
Report date July 02, 2018 · Filed July 03, 2018
Jointly reported with Longitude Capital Partners II, LLC, Longitude Venture Partners II, L.P., Tammenoms Bakker Juliet
Section 16 reporting ended · disclosed 2018-07-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectLongitude Venture Partners II, L.P. | 2,888,155 |
Last balance in matching sequence
After 2018-07-02 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-07-02 · Conversion · Acquired 2,431,511 · Balance 2,431,511 F1: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock. F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). This statement is filed jointly by Longitude Capital Partners II, LLC ("LCP2"), Longitude II, Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP2 is the general partner of Longitude II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. Mr. Enright and Ms. Bakker are the managing members of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. F3: Each of LCP2, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein, and the filing of this statement shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 2 · 2018-07-02 · Conversion · Acquired 456,644 · Balance 2,888,155 F1: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock. F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). This statement is filed jointly by Longitude Capital Partners II, LLC ("LCP2"), Longitude II, Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP2 is the general partner of Longitude II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. Mr. Enright and Ms. Bakker are the managing members of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. F3: Each of LCP2, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein, and the filing of this statement shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectLongitude Venture Partners II, L.P | 3,019,734 |
Reported balance
After 2018-07-02 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-07-02 · Purchase · Acquired 131,579 · Balance 3,019,734 F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). This statement is filed jointly by Longitude Capital Partners II, LLC ("LCP2"), Longitude II, Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP2 is the general partner of Longitude II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. Mr. Enright and Ms. Bakker are the managing members of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. F3: Each of LCP2, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein, and the filing of this statement shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Longitude Venture Partners II, L.P. | 0 |
Reported balance
After 2018-07-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-07-02 · Conversion · Disposed 9,677,419 · Balance 0 F1: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock. F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). This statement is filed jointly by Longitude Capital Partners II, LLC ("LCP2"), Longitude II, Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP2 is the general partner of Longitude II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. Mr. Enright and Ms. Bakker are the managing members of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. F3: Each of LCP2, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein, and the filing of this statement shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Longitude Venture Partners II, L.P. | 0 |
Reported balance
After 2018-07-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-07-02 · Conversion · Disposed 1,817,447 · Balance 0 F1: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock. F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). This statement is filed jointly by Longitude Capital Partners II, LLC ("LCP2"), Longitude II, Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP2 is the general partner of Longitude II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. Mr. Enright and Ms. Bakker are the managing members of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. F3: Each of LCP2, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein, and the filing of this statement shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock was convertible at any time at the option of the holder into Common Stock at a rate of 1/3.98, for no additional consideration, and had no expiration date. Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Common Stock, at a rate of 1/3.98 and for no additional consideration, upon closing of the Issuer's initial public offering of its Common Stock.
F2: These shares are held directly by Longitude Venture Partners II, L.P. ("Longitude II"). This statement is filed jointly by Longitude Capital Partners II, LLC ("LCP2"), Longitude II, Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. LCP2 is the general partner of Longitude II and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II. Mr. Enright and Ms. Bakker are the managing members of LCP2 and may be deemed to share voting and investment power over the shares of the Issuer held by Longitude II.
F3: Each of LCP2, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein, and the filing of this statement shall not be deemed an admission that any such Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 21:17 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,692 | $241.39 | $408,431.88 |
DisclosureSEC source: 0001253886-26-000011 · edgardoc.xml · nonDerivative · entry 2 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,278 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 21:17 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 14 | $244.64 | $3,425.02 |
DisclosureSEC source: 0001253886-26-000011 · edgardoc.xml · nonDerivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,970 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 21:37 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,605 | $0.00 | $0.00 |
DisclosureSEC source: 0001253886-26-000008 · edgardoc.xml · nonDerivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,984 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 22:00 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $18.71 | $0.00 |
DisclosureSEC source: 0001104659-26-075251 · tm2618042-3_4seq1.xml · derivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2036-06-15 F1 · derivative.exercise_date: The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:33 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $15.48 | $0.00 |
DisclosureSEC source: 0001253886-26-000006 · form4-06122026_080600.xml · derivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2036-06-09 F1 · derivative.exercise_date: The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:15 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 17,084 | $0.00 Strike: $34.35 | $0.00 |
DisclosureSEC source: 0001253886-26-000004 · form4-05262026_080520.xml · derivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,084 Underlying: Class A Common Stock · 17,084 shares Expires 2036-05-20 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:03 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,171,121 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005904 · wk-form4_1770336183.xml · derivative · entry 8 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,171,121 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · price: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · derivative.exercise_date: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · derivative.expiration_date: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:03 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,171,121 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005904 · wk-form4_1770336183.xml · derivative · entry 7 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,171,121 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · price: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · derivative.exercise_date: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · derivative.expiration_date: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:03 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,236,631 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005904 · wk-form4_1770336183.xml · derivative · entry 6 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,236,631 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:03 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon Stock | 882,353 | $17.00 | $15,000,001.00 |
DisclosureSEC source: 0001628280-26-005904 · wk-form4_1770336183.xml · nonDerivative · entry 5 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,053,474 F4 · ownership.nature: These shares are held by Longitude 103.8 East, L.P. ("L103"). Longitude 103.8 East Partners, LLC ("L103P") is the general partner of L103 and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of L103P, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of L103P, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:03 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon Stock | 192,647 | $17.00 | $3,274,999.00 |
DisclosureSEC source: 0001628280-26-005904 · wk-form4_1770336183.xml · nonDerivative · entry 4 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,600,399 F2 · ownership.nature: These shares are held by Longitude Venture Partners V, L.P. ("LVPV"). Longitude Capital Partners V, LLC ("LCPV"), is the general partner of LVPV and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of LCPV, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of LCPV, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:03 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionCommon Stock | 1,171,121 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005904 · wk-form4_1770336183.xml · nonDerivative · entry 3 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,171,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · price: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · ownership.nature: These shares are held by Longitude 103.8 East, L.P. ("L103"). Longitude 103.8 East Partners, LLC ("L103P") is the general partner of L103 and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of L103P, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of L103P, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:03 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionCommon Stock | 1,171,121 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005904 · wk-form4_1770336183.xml · nonDerivative · entry 2 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,407,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F3 · price: On February 5, 2026, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners V, L.P. ("LVPV"). Longitude Capital Partners V, LLC ("LCPV"), is the general partner of LVPV and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of LCPV, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of LCPV, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:03 UTC | Veradermics, Inc MANE · Entity 1907 | ConversionCommon Stock | 1,236,631 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-005904 · wk-form4_1770336183.xml · nonDerivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,236,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On February 5, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · ownership.nature: These shares are held by Longitude Venture Partners V, L.P. ("LVPV"). Longitude Capital Partners V, LLC ("LCPV"), is the general partner of LVPV and may be deemed to have voting, investment and dispositive power with respect to these shares. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of LCPV, and may each be deemed to share voting, investment and dispositive power with respect to these shares. Each of LCPV, Ms. Tammenoms Bakker and the Reporting Person disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 16:26 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | SaleClass A Common Stock | 49,000 | $3.88 | $190,090.60 |
DisclosureSEC source: 0001193125-26-041248 · ownership.xml · nonDerivative · entry 1 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner Longitude Prime Fund, L.P. · CIK 0001865844 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Longitude Prime Fund, L.P. Disclosed balance after: 0 F1 · ownership.nature: The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and dispositive power with respect to the shares held by LPF. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP and may be deemed to have voting and dispositive power over the shares held by LPF. LPP and each of Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document |
| February 03, 2026 Filed Feb 3, 2026 20:50 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | SaleClass A Common Stock | 27,500 | $4.24 | $116,641.25 |
DisclosureSEC source: 0001193125-26-036387 · ownership.xml · nonDerivative · entry 5 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Longitude Prime Fund, L.P. Disclosed balance after: 49,000 F3 · ownership.nature: The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and dispositive power with respect to the shares held by LPF. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP and may be deemed to have voting and dispositive power over the shares held by LPF. LPP and each of Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 00:03 UTC | Veradermics, Inc MANE · Entity 1907 | GrantStock Option (Right to Buy) · Derivative | 45,131 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001628280-26-005904 · wk-form4_1770336183.xml · derivative · entry 9 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,131 Underlying: Common Stock · 45,131 shares Expires 2036-02-03 F5 · derivative.exercise_date: This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 20:50 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | SaleClass A Common Stock | 27,500 | $4.25 | $116,765.00 |
DisclosureSEC source: 0001193125-26-036387 · ownership.xml · nonDerivative · entry 4 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Longitude Prime Fund, L.P. Disclosed balance after: 76,500 F3 · ownership.nature: The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and dispositive power with respect to the shares held by LPF. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP and may be deemed to have voting and dispositive power over the shares held by LPF. LPP and each of Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 20:50 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | SaleClass A Common Stock | 46,000 | $4.54 | $209,001.00 |
DisclosureSEC source: 0001193125-26-036387 · ownership.xml · nonDerivative · entry 3 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Longitude Prime Fund, L.P. Disclosed balance after: 104,000 F3 · ownership.nature: The securities are held directly by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP"), the general partner of LPF, may be deemed to have voting and dispositive power with respect to the shares held by LPF. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LPP and may be deemed to have voting and dispositive power over the shares held by LPF. LPP and each of Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. Read SEC document |
| January 23, 2026 Filed Feb 3, 2026 20:50 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | OtherClass A Common Stock · Derivative | 129,032 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0001193125-26-036387 · ownership.xml · derivative · entry 7 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Class A Common Stock · 129,032 shares Expires 2028-01-17 F4 · derivative.exercise_date: The warrant is immediately exercisable. F2 · ownership.nature: The securities are held directly by LVPII. Longitude Capital Partners II, LLC, ("LCPII"), the general partner of LVPII, may be deemed to have voting and dispositive power with respect to the shares held by LVPII. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPII and may be deemed to share voting and dispositive power over the shares held by LVPII. Each of LCPII, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document |
| January 23, 2026 Filed Feb 3, 2026 20:50 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | OtherClass A Common Stock · Derivative | 500,000 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0001193125-26-036387 · ownership.xml · derivative · entry 6 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 0 Underlying: Class A Common Stock · 500,000 shares Expires 2027-07-24 F4 · derivative.exercise_date: The warrant is immediately exercisable. F2 · ownership.nature: The securities are held directly by LVPII. Longitude Capital Partners II, LLC, ("LCPII"), the general partner of LVPII, may be deemed to have voting and dispositive power with respect to the shares held by LVPII. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPII and may be deemed to share voting and dispositive power over the shares held by LVPII. Each of LCPII, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document |
| January 23, 2026 Filed Feb 3, 2026 20:50 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | SaleClass A Common Stock | 7,739 | $4.06 | $31,451.30 |
DisclosureSEC source: 0001193125-26-036387 · ownership.xml · nonDerivative · entry 2 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 4,029,245 F1 · kind: Longitude Venture Partners II, L.P. ("LVPII") exercised warrants to purchase an aggregate of 629,032 shares of the Issuer's Class A common stock for $0.05 per share and paid the exercise price on a cashless basis, resulting in the Issuer withholding 7,739 shares of the Issuer's shares of Class A common stock subject to the warrant to pay the exercise price. F2 · ownership.nature: The securities are held directly by LVPII. Longitude Capital Partners II, LLC, ("LCPII"), the general partner of LVPII, may be deemed to have voting and dispositive power with respect to the shares held by LVPII. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPII and may be deemed to share voting and dispositive power over the shares held by LVPII. Each of LCPII, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document |
| January 23, 2026 Filed Feb 3, 2026 20:50 UTC | RAPID MICRO BIOSYSTEMS, INC. RPID · Entity 6966 | OtherClass A Common Stock | 629,032 | $0.05 | $31,451.60 |
DisclosureSEC source: 0001193125-26-036387 · ownership.xml · nonDerivative · entry 1 Longitude Capital Partners II, LLC · CIK 0001647491 · 10% owner Longitude Venture Partners II, L.P. · CIK 0001527510 · 10% owner Longitude Prime Partners, LLC · CIK 0001865779 · 10% owner ENRIGHT PATRICK G · CIK 0001253886 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Longitude Venture Partners II, L.P. Disclosed balance after: 4,036,984 F1 · kind: Longitude Venture Partners II, L.P. ("LVPII") exercised warrants to purchase an aggregate of 629,032 shares of the Issuer's Class A common stock for $0.05 per share and paid the exercise price on a cashless basis, resulting in the Issuer withholding 7,739 shares of the Issuer's shares of Class A common stock subject to the warrant to pay the exercise price. F2 · ownership.nature: The securities are held directly by LVPII. Longitude Capital Partners II, LLC, ("LCPII"), the general partner of LVPII, may be deemed to have voting and dispositive power with respect to the shares held by LVPII. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of LCPII and may be deemed to share voting and dispositive power over the shares held by LVPII. Each of LCPII, Mr. Enright and Ms. Tammenoms Bakker disclaim beneficial ownership of such securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein. Read SEC document |
| December 11, 2025 Filed Dec 16, 2025 01:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | PurchaseClass A Common Stock | 5,882 | $42.50 | $249,985.00 |
DisclosureSEC source: 0001193125-25-319649 · ownership.xml · nonDerivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,882 Read SEC document |
| October 09, 2025 Filed Oct 14, 2025 12:59 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 11,990 | $20.85 | $249,991.50 |
DisclosureSEC source: 0001193125-25-238326 · ownership.xml · nonDerivative · entry 2 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,990 F1 · price: On October 7, 2025, the Issuer entered into a Securities Purchase Agreement with certain investors, including the Reporting Person and Longitude Venture Partners IV, L.P. ("LVPIV") pursuant to which the Reporting Person purchased 11,990 shares of common stock at a price per share of $20.85 and LVPIV purchased 105,265 shares of common stock as a price per share of $19.00 (the "Offering"). The Offering closed on October 9, 2025. Read SEC document |
| October 09, 2025 Filed Oct 14, 2025 12:59 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 105,265 | $19.00 | $2,000,035.00 |
DisclosureSEC source: 0001193125-25-238326 · ownership.xml · nonDerivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,832,669 F1 · price: On October 7, 2025, the Issuer entered into a Securities Purchase Agreement with certain investors, including the Reporting Person and Longitude Venture Partners IV, L.P. ("LVPIV") pursuant to which the Reporting Person purchased 11,990 shares of common stock at a price per share of $20.85 and LVPIV purchased 105,265 shares of common stock as a price per share of $19.00 (the "Offering"). The Offering closed on October 9, 2025. F2 · ownership.nature: Shares held by LVPIV. Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. Juliet Tammenoms Bakker and the Reporting Person, a member of the board of directors of the Issuer, are the managing members of LCPIV and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of LCPIV, Ms. Bakker and the Reporting Person disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 18, 2025 Filed Jan 8, 2026 22:56 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | OtherOrdinary Shares | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001253886-26-000002 · edgardoc.xml · nonDerivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,379 F1 · kind: Shares transferred to former spouse without consideration as part of a comprehensive division of marital assets. Following the transfer, the reporting person no longer has beneficial ownership of the transferred shares. Read SEC document |
| August 08, 2025 Filed Aug 11, 2025 21:46 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,805 | $111.25 | $200,804.63 |
DisclosureSEC source: 0001765581-25-000092 · edgardoc.xml · nonDerivative · entry 2 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,379 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 21:46 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000092 · edgardoc.xml · nonDerivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,184 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 00:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | PurchaseClass A Common Stock | 27,071 | $22.35 | $605,082.87 |
DisclosureSEC source: 0000950170-25-090110 · ownership.xml · nonDerivative · entry 4 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,596,593 F4 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $21.67 to $22.50, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4. F3 · ownership.nature: These shares are held by Longitude Venture Partners IV, L.P ("LVPIV"). Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting and dispositive power over the shares held by LVPIV. The Reporting Person and Ms. Tammenoms Bakker are managing members of LCPIV and may be deemed to share voting and dispositive power with respect to the shares held by LVPIV. Each of LCPIV, the Reporting Person and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 00:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | PurchaseClass A Common Stock | 13,536 | $22.35 | $302,552.61 |
DisclosureSEC source: 0000950170-25-090110 · ownership.xml · nonDerivative · entry 3 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,797,619 F4 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $21.67 to $22.50, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4. F2 · ownership.nature: These shares are held by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. The Reporting Person and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting and dispositive power over the shares held by LPF. Each of LPP, the Reporting Person and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 23, 2025 Filed Jun 26, 2025 00:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | PurchaseClass A Common Stock | 139,595 | $20.87 | $2,913,110.34 |
DisclosureSEC source: 0000950170-25-090110 · ownership.xml · nonDerivative · entry 2 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,569,522 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $20.43 to $21.05, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F3 · ownership.nature: These shares are held by Longitude Venture Partners IV, L.P ("LVPIV"). Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting and dispositive power over the shares held by LVPIV. The Reporting Person and Ms. Tammenoms Bakker are managing members of LCPIV and may be deemed to share voting and dispositive power with respect to the shares held by LVPIV. Each of LCPIV, the Reporting Person and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 23, 2025 Filed Jun 26, 2025 00:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | PurchaseClass A Common Stock | 69,798 | $20.87 | $1,456,565.60 |
DisclosureSEC source: 0000950170-25-090110 · ownership.xml · nonDerivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,784,083 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $20.43 to $21.05, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4. F2 · ownership.nature: These shares are held by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. The Reporting Person and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting and dispositive power over the shares held by LPF. Each of LPP, the Reporting Person and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:33 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $11.94 | $0.00 |
DisclosureSEC source: 0001104659-25-058924 · tm2517684-4_4seq1.xml · derivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: The option vests as to 100% of the underlying shares of common stock on June 10, 2026, the first anniversary of the vesting commencement date, subject to continued service. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:44 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001415889-25-016286 · form4-06092025_080600.xml · derivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:13 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $21.19 | $0.00 |
DisclosureSEC source: 0001415889-25-013421 · form4-05162025_080556.xml · derivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Class A Common Stock · 14,000 shares Expires 2035-05-13 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 20:26 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | ConversionSeries D Preferred Stock · Derivative | 5,848,637 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-024046 · form4-09272024_080937.xml · derivative · entry 4 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Longitude Venture Partners IV, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,310,589 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614. The securities have no expiration date. F1 · price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614. The securities have no expiration date. F1 · derivative.exercise_date: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614. The securities have no expiration date. F1 · derivative.expiration_date: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614. The securities have no expiration date. F2 · ownership.nature: These shares are directly held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to exercise voting and investment discretion with respect to securities held by LVP IV. The reporting person and Ms. Juliet Tammenoms Bakker serve as the managing members of LCP IV and may be deemed to share voting and investment discretion with respect to securities held directly by LVP IV. Each of LCP IV, Mr. Enright, and Ms. Tammenoms Bakker disclaims beneficial ownership of such securities and this report shall not be deemed an admission that any of them is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 20:26 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | PurchaseCommon Stock | 400,000 | $18.00 | $7,200,000.00 |
DisclosureSEC source: 0001415889-24-024046 · form4-09272024_080937.xml · nonDerivative · entry 2 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Longitude Venture Partners IV, L.P. Disclosed balance after: 1,710,589 F2 · ownership.nature: These shares are directly held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to exercise voting and investment discretion with respect to securities held by LVP IV. The reporting person and Ms. Juliet Tammenoms Bakker serve as the managing members of LCP IV and may be deemed to share voting and investment discretion with respect to securities held directly by LVP IV. Each of LCP IV, Mr. Enright, and Ms. Tammenoms Bakker disclaims beneficial ownership of such securities and this report shall not be deemed an admission that any of them is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 20:26 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | ConversionCommon Stock | 1,310,589 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-024046 · form4-09272024_080937.xml · nonDerivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Longitude Venture Partners IV, L.P. Disclosed balance after: 1,310,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.224084614. The securities have no expiration date. F2 · ownership.nature: These shares are directly held by Longitude Venture Partners IV, L.P ("LVP IV"). Longitude Capital Partners IV, LLC ("LCP IV") is the general partner of LVP IV and may be deemed to exercise voting and investment discretion with respect to securities held by LVP IV. The reporting person and Ms. Juliet Tammenoms Bakker serve as the managing members of LCP IV and may be deemed to share voting and investment discretion with respect to securities held directly by LVP IV. Each of LCP IV, Mr. Enright, and Ms. Tammenoms Bakker disclaims beneficial ownership of such securities and this report shall not be deemed an admission that any of them is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 25, 2024 Filed Sep 27, 2024 20:26 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024046 · form4-09272024_080937.xml · derivative · entry 3 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-09-24 F3 · derivative.exercise_date: The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 00:57 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionSeries C Convertible Preferred Stock · Derivative | 2,904,764 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100333 · tm2424157-3_4seq1.xml · derivative · entry 7 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 334,530 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · shares: Shares held by LPF. F1 · price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.exercise_date: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.expiration_date: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · derivative.underlying_shares: Shares held by LPF. F3 · ownership.nature: Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. Longitude Prime Partners, LLC ("LPP") is the general partner of Longitude Prime Fund, L.P. ("LPF") and may be deemed to have voting, investment and dispositive power with respect to the securities held by LPF. Juliet Tammenoms Bakker and Patrick G. Enright, a member of the board of directors of the Issuer, are the managing members of LCPIV and LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of LCPIV, LPP, Ms. Bakker and Mr. Enright disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 00:57 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionSeries C Convertible Preferred Stock · Derivative | 8,714,293 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100333 · tm2424157-3_4seq1.xml · derivative · entry 6 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,003,592 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · shares: Shares held by Longitude Venture Partners IV, L.P. ("LVPIV"). F1 · price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.exercise_date: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · derivative.expiration_date: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · derivative.underlying_shares: Shares held by Longitude Venture Partners IV, L.P. ("LVPIV"). F3 · ownership.nature: Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. Longitude Prime Partners, LLC ("LPP") is the general partner of Longitude Prime Fund, L.P. ("LPF") and may be deemed to have voting, investment and dispositive power with respect to the securities held by LPF. Juliet Tammenoms Bakker and Patrick G. Enright, a member of the board of directors of the Issuer, are the managing members of LCPIV and LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of LCPIV, LPP, Ms. Bakker and Mr. Enright disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 00:57 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionSeries B Convertible Preferred Stock · Derivative | 6,284,933 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100333 · tm2424157-3_4seq1.xml · derivative · entry 5 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 723,812 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · shares: Shares held by Longitude Venture Partners IV, L.P. ("LVPIV"). F1 · price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.exercise_date: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · derivative.expiration_date: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · derivative.underlying_shares: Shares held by Longitude Venture Partners IV, L.P. ("LVPIV"). F3 · ownership.nature: Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. Longitude Prime Partners, LLC ("LPP") is the general partner of Longitude Prime Fund, L.P. ("LPF") and may be deemed to have voting, investment and dispositive power with respect to the securities held by LPF. Juliet Tammenoms Bakker and Patrick G. Enright, a member of the board of directors of the Issuer, are the managing members of LCPIV and LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of LCPIV, LPP, Ms. Bakker and Mr. Enright disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 00:57 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | PurchaseCommon Stock | 440,000 | $17.00 | $7,480,000.00 |
DisclosureSEC source: 0001104659-24-100333 · tm2424157-3_4seq1.xml · nonDerivative · entry 4 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 774,530 F5 · balance_after: Shares held by LPF. F3 · ownership.nature: Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. Longitude Prime Partners, LLC ("LPP") is the general partner of Longitude Prime Fund, L.P. ("LPF") and may be deemed to have voting, investment and dispositive power with respect to the securities held by LPF. Juliet Tammenoms Bakker and Patrick G. Enright, a member of the board of directors of the Issuer, are the managing members of LCPIV and LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of LCPIV, LPP, Ms. Bakker and Mr. Enright disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 00:57 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionCommon Stock | 334,530 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100333 · tm2424157-3_4seq1.xml · nonDerivative · entry 3 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 334,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F5 · balance_after: Shares held by LPF. F3 · ownership.nature: Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. Longitude Prime Partners, LLC ("LPP") is the general partner of Longitude Prime Fund, L.P. ("LPF") and may be deemed to have voting, investment and dispositive power with respect to the securities held by LPF. Juliet Tammenoms Bakker and Patrick G. Enright, a member of the board of directors of the Issuer, are the managing members of LCPIV and LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of LCPIV, LPP, Ms. Bakker and Mr. Enright disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 00:57 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionCommon Stock | 1,003,592 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100333 · tm2424157-3_4seq1.xml · nonDerivative · entry 2 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,727,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F4 · price: On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · balance_after: Shares held by Longitude Venture Partners IV, L.P. ("LVPIV"). F3 · ownership.nature: Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. Longitude Prime Partners, LLC ("LPP") is the general partner of Longitude Prime Fund, L.P. ("LPF") and may be deemed to have voting, investment and dispositive power with respect to the securities held by LPF. Juliet Tammenoms Bakker and Patrick G. Enright, a member of the board of directors of the Issuer, are the managing members of LCPIV and LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of LCPIV, LPP, Ms. Bakker and Mr. Enright disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 00:57 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | ConversionCommon Stock | 723,812 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-100333 · tm2424157-3_4seq1.xml · nonDerivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 723,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F1 · price: On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. F2 · balance_after: Shares held by Longitude Venture Partners IV, L.P. ("LVPIV"). F3 · ownership.nature: Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. Longitude Prime Partners, LLC ("LPP") is the general partner of Longitude Prime Fund, L.P. ("LPF") and may be deemed to have voting, investment and dispositive power with respect to the securities held by LPF. Juliet Tammenoms Bakker and Patrick G. Enright, a member of the board of directors of the Issuer, are the managing members of LCPIV and LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities. Each of LCPIV, LPP, Ms. Bakker and Mr. Enright disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 12, 2024 Filed Sep 17, 2024 00:57 UTC | Zenas BioPharma, Inc. ZBIO · Entity 275 | GrantStock Option (Right to Buy) · Derivative | 37,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-24-100333 · tm2424157-3_4seq1.xml · derivative · entry 8 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2034-09-11 F6 · derivative.exercise_date: The option vests in equal annual installments over three years beginning on September 12, 2025, the first anniversary of the vesting commencement date, subject to continued service. Read SEC document |
| August 02, 2024 Filed Aug 6, 2024 22:45 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-24-000080 · edgardoc.xml · nonDerivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,677 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 25, 2025. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:10 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $42.69 | $0.00 |
DisclosureSEC source: 0001415889-24-013472 · form4-05172024_080506.xml · derivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Class A Common Stock · 14,000 shares Expires 2034-05-14 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.